Hologic (HOLX) has had an interesting run lately with fluctuations in the broader market. As per the reports, it has seen both rises and falls more steeply than the overall market. Despite a bearish outlook by Zacks Research for Q1 earnings, HOLX has managed to present at three major healthcare investment conferences. It has seen major movements in its shares, with the notable acquisition of 238,222 shares by JPMorgan Chase & Co and being purchased by Principal Financial Group Inc, denoting investor interest. It has also seen an increase in short interest and has been rated as a long-term value and momentum stock. Its recent Q4 earnings were marked by some missed estimates but also reported strong revenue growth amid challenges. It's important to note the ups and downs of its stock price, recently touching a 52-week low. Despite a recall over safety concerns, the company has garnered interest with its advanced Genius AI Detection PRO for unbiased breast cancer screening. On the other hand, it had to face a downgrade by Citi, citing overestimated FY25 growth.
Hologic HOLX News Analytics from Fri, 10 Nov 2023 08:00:00 GMT to Fri, 03 Jan 2025 11:46:08 GMT -
Rating -1
- Innovation 3
- Information 7
- Rumor 4
